Epidemiologic Study of Hepatocellular Carcinoma in the US

March 20, 2020 updated by: Stanford University

The purpose of this study is:

  • to investigate the risk factors of HCC among Americans with focus on lifestyle factors and energy balance.
  • to identify single nucleotide polymorphisms (SNPs) and haplotypes that are associated with HCC risk through a genome-wide search.
  • to assess if genetic susceptibility differs by hepatitis virus infection or lifestyle factors, and to explore if there are interplays or effect modifications between genetic factors and viral infection or lifestyle factors.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

45

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Stanford, California, United States, 94305
        • Stanford Liver Transplant Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 84 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients with Hepatocellular Carcinoma in New Jersey and Connecticut as well as selected patients in New York, Hawaii and northern California.

Healthy volunteers will comprise a random sample of New Jersey and Connecticut residents as controls.

Description

Inclusion Criteria for HCC cases:

  • a diagnosis of primary liver cancer (excluding secondary tumors)
  • a diagnosis of hepatocellular carcinoma if histology is available (excluding those diagnosed in intrahepatic bile duct, bile canals, biliary passages, canaliculi, gall duct and gallbladder)
  • a diagnosis of hepatocellular carcinoma with or without microscopic evaluation (including those diagnosed with clinical evidence, lab tests and direct visualization or radiographic and other imaging evidence)
  • a histology of primary hepatocellular carcinoma when the patients had a prior diagnosis of other forms of cancer (excluding those who had no histological diagnosis of hepatocellular carcinoma while having a prior history of other cancer;
  • age at diagnosis between 35 and 84 years
  • living in Connecticut, New Jersey, New York, or Hawaii for at least a year as regular residents.

Exclusion Criteria for HCC cases:

  • uncertain diagnoses or classification of malignancy, such as unknown origin
  • a diagnosis of primary tumors in other organs, not in the liver
  • unable to communicate well enough in English or Spanish
  • having medical conditions, such as mental disorders, that prevent the subject from providing reasonably comprehensible information or from being able to give informed consent.
  • diagnosed at age <35 years or >84 years
  • temporary residents of New Jersey, Connecticut, New York, or Hawaii

Inclusion Criteria for control subjects:

  • age between 35 and 84 years
  • living in New Jersey or Connecticut for at least a year as regular residents
  • able to communicate well in English or Spanish
  • having no medical conditions, such as mental disorders, that prevent them from providing adequately comprehensible information
  • potential subjects with a previous history of cancer are eligible.

Exclusion Criteria for control subjects:

  • age < 35 years or > 84 years
  • temporary residents of New Jersey or Connecticut
  • unable to speak English or Spanish
  • cannot provide adequately comprehensible information

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
control group
HCC group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lifetime physical activity
Time Frame: 20 years
Lifetime physical activity will be measured by collecting data on major types of physical activity separately and by determining frequency, intensity, and duration of each activity using a combined modification of Friedenreich's lifetime physical activity questionnaire and Kriska's past year physical activity questionnaires.
20 years
Energy intake
Time Frame: 20 years
A modified Food Frequency questionnaire based on one developed by Dr. Alan Kristal from the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle will capture energy intake by differentiating low-fat food options from higher-fat counterparts.
20 years
Lifestyle factors
Time Frame: 20 years
Structured questionnaires will be used to elicit information on demographic, anthropometric, and socioeconomic factors, long-term use of medications, medical history, and family history of cancer, cigarette smoking and alcohol consumption, physical activity, and dietary habits. Additional information unrelated to liver cancer will be included in the questionnaire to help assess possible recall bias.
20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mindie Nguyen, MD, Stanford University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2015

Primary Completion (Actual)

September 1, 2016

Study Completion (Actual)

September 1, 2016

Study Registration Dates

First Submitted

January 29, 2015

First Submitted That Met QC Criteria

February 5, 2015

First Posted (Estimate)

February 6, 2015

Study Record Updates

Last Update Posted (Actual)

March 24, 2020

Last Update Submitted That Met QC Criteria

March 20, 2020

Last Verified

March 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

3
Subscribe